Environmental Scan 2017: Human Capital Issues within the Medical Devices Sector
Benchmarked Countries
Description
different stakeholders within the healthcare and medical
technology ecosystem. Their key stakeholders consist of
a diverse range of people including clinicians,
governments, regulators, healthcare providers and
manufacturers of medical devices.
As of 2015, Singapore’s medical technology sector
contributed to more than S$ 10 Billion worth of output
while creating approximately 16,000 jobs across
manufacturing, R&D and operations.
Medical Device Industry Growth Drivers
Singapore has a strong advantage in terms of its
geographical location and the availability of a wide range
of niche businesses in the country
The presence of two Medical Technology hub in
Singapore Biopolis and Tuas Biomedical Park.
o These parks focus on research and development,
manufacturing and healthcare to complete the
entire ecosystem. The Singapore Biopolis also
plays a pivotal role in bringing together major
research institutes to create a center of
excellence and serves as a focal point in
attracting top scientific talents to Singapore.
The strong presence of skilled workforce within all sub
verticals within the healthcare industry further enhances
the medical devices landscape in Singapore. The talented
and experienced workforce support a wide range of
corporate laboratories and both domestic and
international pharmaceutical companies.
Strong collaboration between scientists and researchers
from research agencies like A*STAR and industry to
exchange ideas and explore collaborations, facilitating
commercialization of research outputs. This is a very
important component in the development of new and
innovative medical devices moving forward.
The other driver that encourages innovation in Singapore
is the ability of private sector laboratories to make use
of shared infrastructure
The government has spent close to $2bn over the last few
years by investing in infrastructure and biomedical
capabilities while allocating more than $3bn between
2011 to 2015 to support biomedical enterprises and
research works.
164